Lever R, Hadley K, Downey D, Mackie R
Department of Dermatology, University of Glasgow, U.K.
Br J Dermatol. 1988 Aug;119(2):189-98. doi: 10.1111/j.1365-2133.1988.tb03201.x.
Forty-nine patients with atopic dermatitis entered a double blind placebo controlled cross-over study of mupirocin, a new topical antistaphylococcal antibiotic. Forty-five patients were evaluable. Quantitative bacteriological assessment before treatment showed that heavy colonization of the skin with Staphylococcus aureus was present in nearly all patients even in the absence of overt infection. However, the bacterial count was significantly reduced by 2 weeks' treatment with topical mupirocin, but not by the placebo. Moreover, a significant reduction of clinical severity was also observed after treatment with mupirocin, which was maintained over the following 4 weeks, although recolonization occurred during this period, with bacterial counts rising to pre-treatment levels. Despite recolonization, clinical deterioration was not observed during the trial period. No serious side-effects were observed. Phage typing showed that 50% of patients carried more than one bacterial phage type. Recolonization in eight patients (17%) was with a 'new' strain that had not previously been isolated.
49例特应性皮炎患者参与了一项关于新型外用抗葡萄球菌抗生素莫匹罗星的双盲安慰剂对照交叉研究。45例患者可进行评估。治疗前的定量细菌学评估显示，几乎所有患者的皮肤都被金黄色葡萄球菌重度定植，即便没有明显感染。然而，外用莫匹罗星治疗2周后细菌计数显著降低，而安慰剂治疗则无此效果。此外，莫匹罗星治疗后临床严重程度也显著降低，在接下来的4周内保持这种状态，尽管在此期间发生了重新定植，细菌计数回升至治疗前水平。尽管重新定植，但在试验期间未观察到临床病情恶化。未观察到严重副作用。噬菌体分型显示，50%的患者携带不止一种细菌噬菌体类型。8例患者（17%）重新定植的是之前未分离出的“新”菌株。
